Strategic Wealth Advisors Group LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 9.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 57,088 shares of the company’s stock after acquiring an additional 4,904 shares during the period. Strategic Wealth Advisors Group LLC’s holdings in Johnson & Johnson were worth $7,417,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Virtus ETF Advisers LLC bought a new stake in Johnson & Johnson in the second quarter worth about $25,000. Krane Funds Advisors LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $26,000. Financial Advantage Inc. purchased a new position in shares of Johnson & Johnson during the third quarter worth approximately $28,000. Crewe Advisors LLC increased its position in shares of Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after acquiring an additional 196 shares during the period. Finally, Permanens Capital L.P. increased its position in shares of Johnson & Johnson by 50.0% during the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after acquiring an additional 100 shares during the period. 72.22% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have recently commented on JNJ. Credit Suisse Group raised their target price on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price on the stock in a research report on Thursday, October 17th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Wells Fargo & Co reduced their target price on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 16th. Finally, Bank of America reaffirmed a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus target price of $151.64.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company posted $2.05 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post 8.65 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 2.89%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s payout ratio is 46.45%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Which market index is the best?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.